<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C0D1CA6E-1770-4AA4-9EC0-55336CC1D676"><gtr:id>C0D1CA6E-1770-4AA4-9EC0-55336CC1D676</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:surname>Dore</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F14"><gtr:id>2E89EF10-148F-4EA3-9E5E-7718C63F8E0B</gtr:id><gtr:title>Improving Prevention and Treatment for Patients with Musculoskeletal Conditions.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/14</gtr:grantReference><gtr:abstractText>VIDEO and PACINO are two of our current clinical trials which aim to find better ways of treating patients with musculoskeletal conditions.||In the VIDEO trial patients with osteoarthritis of the knee are randomised to either daily Vitamin D or placebo capsules for three years. We want to find out whether Vitamin D will slow down the rate of narrowing of the joint space width in the knee. Patients have X-rays of their knee at the start of the trial and after three years of therapy and complete regular questionnaires describing their pain and disability. If Vitamin D is found to be effective we hope this will improve pain, function and the need for knee replacement surgery for these patients.||PACINO is a trial in patients who have a fracture of the lower leg (tibia) which is not healing. The usual surgical procedure after removing areas of damaged bone is to drill holes in the healthy bone where the two bones meet and fill these holes with the patients bone marrow to try to encourage the growth of new bone to fill the gap. We want to find out whether inserting stem cells grown from the patients bone marrow will make the new bone grow faster. Patients would welcome any decrease in the time they have to spend wearing a metal frame to support their unhealed fracture.</gtr:abstractText><gtr:technicalSummary>The aim of the programme is to improve prevention and treatment for patients with musculoskeletal conditions. These are a major problem both nationally and internationally with a high burden of disability, and will become increasingly important as a consequence of the ageing population.||Arthritis Research UK is one of the largest medical research charities in the UK, funding research into the causes, consequences and treatment of musculoskeletal conditions. In 2008 Arthritis Research UK launched their clinical studies initiative to develop a comprehensive research programme in partnership with the UK Clinical Research Network (CRN), industry and other funders (such as NIHR) that would permit the testing of both new and existing interventions, based on a nationally agreed and scientifically robust research agenda, across the major disease areas of the charitys interests. In achieving this, there would be a transformation of clinical practice in areas of relevance which would drive both knowledge advance and quality of care. All their UK funded trials will be conducted by UKCRC registered trials units. The charity has funded a senior statistician post at the CTU since 2001 to advise researchers developing proposals for these clinical studies.||Osteoarthritis is a common disorder, and at present there are no effective treatments that alter disease pathology. Management of osteoarthritis is primarily aimed at symptom control with the aim to retain or improve joint function. Epidemiological data suggest that low dietary intake of vitamin D and low serum 25-hydroxyvitamin D3 levels are associated with radiological progression in knee osteoarthritis. VIDEO is a three year randomised, double-blind, placebo controlled trial funded by Arthritis Research UK to determine whether vitamin D supplementation of cholecalciferol 800 IU daily can reduce the rate of disease progression and improve symptoms in participants with knee osteoarthritis. The primary outcome measure is radiological progression with secondary endpoints being symptoms and quality of life assessments. As Vitamin D supplementation is safe and cheap, any proven benefit in the management of osteoarthritis will have important relevance to healthcare in the elderly.||Since 2007 the Royal National Orthopaedic Hospital have funded a statistician post to at the CTU to work on orthopaedic studies. A strong research theme of the Royal National Orthopaedic Hospital is a regenerative approach to lesions of cartilage, bone and tendon using cell-based therapies. If such an approach can be made to work this would reduce the need for reconstructive surgery and improve quality of life by reducing the amount of time the patient has to spend with their leg in a metal frame. RNOH have secured MRC funding to conduct a trial (PACINO) of autologous mesenchymal stem cells in fracture non-union. At the end of the trial we will use proteomics to correlate clinical response with cell phenotype. This should enable us to refine cell culture processes, and hence to develop more effective treatments for future trials.||A Phase II trial (SCARAB) of autologous bone marrow derived mesenchymal stem cells mixed with bone stock to improve the regeneration of bone adjacent to the implant in revision hip surgery is being planned. The failure rate of revision hip surgery is high, 25-50% of revision procedures fail, and increasing the regeneration of bone within the impacted graft is crucial for a successful outcome.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>83000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Workshop to develop guidance for internal pilot studies</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D1069E43-66E9-4A23-8A87-8EDB45CE10FB</gtr:id><gtr:impact>This was a workshop to optimise the design and evaluation of internal pilot work to inform efficient randomised controlled trials. I presented a vignette describing the internal pilot phase and the progression criteria for the TARVA trial. The workshop was funded by the MRC Hubs for Trials Methodology research. A paper summarising the discussion is in preparation</gtr:impact><gtr:outcomeId>56cb12228a20a5.97589661</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Cochrane review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DEDCAD36-4D4F-476F-A96B-399A54B0033D</gtr:id><gtr:impact>Rehabilitation following lumbar disc surgery</gtr:impact><gtr:outcomeId>56cb206e920e86.03966299</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/24627325</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9047BB71-EDEE-4B6F-87C1-97C095022048</gtr:id><gtr:title>EFFECT OF VITAMIN D SUPPLEMENTATION ON RADIOGRAPHIC KNEE OSTEOARTHRITIS</gtr:title><gtr:parentPublicationTitle>OSTEOARTHRITIS AND CARTILAGE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cf7d3f106903de2b7de7303fe44ee5b"><gtr:id>9cf7d3f106903de2b7de7303fe44ee5b</gtr:id><gtr:otherNames>Arden N. K.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1063-4584</gtr:issn><gtr:outcomeId>56bc72ecbfc263.57876207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61B8CBF4-6BB6-4815-A7FA-2CEAA7E83093</gtr:id><gtr:title>OPTIMIZING TREATMENT WITH TNF INHIBITORS IN RHEUMATOID ARTHRITIS: IS DOSE TAPERING PRACTICAL IN OPTIMAL RESPONDERS? THE OPTTIRA TRIAL</gtr:title><gtr:parentPublicationTitle>RHEUMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aad2b77a16d5af48131e818b4c54a1d"><gtr:id>8aad2b77a16d5af48131e818b4c54a1d</gtr:id><gtr:otherNames>Galloway James</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56bc7246302528.14701897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3444F9AC-09CD-4F12-BAA6-A9C49E511234</gtr:id><gtr:title>Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09d859c0f8335ca40009b99e4329d87a"><gtr:id>09d859c0f8335ca40009b99e4329d87a</gtr:id><gtr:otherNames>Cohen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>56bc6fb665ce23.64807062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>108BF9C1-9C52-4EA9-BC77-AD04A4753899</gtr:id><gtr:title>RAPS: a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE</gtr:title><gtr:parentPublicationTitle>JOURNAL OF THROMBOSIS AND HAEMOSTASIS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4112b0339ae57589cec8889beb7423"><gtr:id>7b4112b0339ae57589cec8889beb7423</gtr:id><gtr:otherNames>Cohen H.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7933</gtr:issn><gtr:outcomeId>56bc73d2ca8f95.46336276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2772DAC3-144F-4D60-BA3D-C59E5BAFD0D4</gtr:id><gtr:title>Interventions in randomised controlled trials in surgery: issues to consider during trial design.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/358b24fc3fa6ab7e39ee3c04a3952913"><gtr:id>358b24fc3fa6ab7e39ee3c04a3952913</gtr:id><gtr:otherNames>Blencowe NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56bb75db293968.27125554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A798542-A116-4236-B59F-17E2BC3B2C3B</gtr:id><gtr:title>Raps (rivaroxaban in antiphospholipid syndrome): a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE</gtr:title><gtr:parentPublicationTitle>JOURNAL OF THROMBOSIS AND HAEMOSTASIS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4112b0339ae57589cec8889beb7423"><gtr:id>7b4112b0339ae57589cec8889beb7423</gtr:id><gtr:otherNames>Cohen H.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1538-7933</gtr:issn><gtr:outcomeId>56bc71fb0540a8.50044803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4860B45C-6CB9-42F6-A238-F2AAF4522DC9</gtr:id><gtr:title>Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c49755f7f5b167b37c218aa065bc555"><gtr:id>5c49755f7f5b167b37c218aa065bc555</gtr:id><gtr:otherNames>Ibrahim F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56bb75dac07f61.04176399</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/14</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>4CFCFE99-281F-452D-9C77-757ECDBEB0DC</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.3  Medical devices</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>